Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test

NCT ID: NCT02190578

Last Updated: 2015-04-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 1649 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2015-03-31

Brief Summary

To determine the efficacy of an improved rapid diagnostic test using venous whole blood and fingerstick whole blood. The clinical performance of Reveal G4 Rapid HIV-1 Antibody Test will be determined by comparing the results with patient infected status for HIV-1 (human immunodeficiency virus type 1).

The study will consist of a single one-hour visit, at which time blood samples will be collected and tested with the investigational device (Reveal G4) and FDA approved comparator assays for detection of HIV-1 antibodies.

Detailed Description

This clinical trial is a multi-center study to assess the performance characteristics of a rapid in vitro diagnostic assay, the Reveal G4 Rapid HIV-1 Antibody Test (Reveal G4). Specifically, the objective of this study is to determine the sensitivity and specificity of Reveal G4 in finger stick and venous whole blood, relative to FDA approved reference assays for the detection of HIV-1 antibodies.

Approximately 1500-2000 subjects in total will be enrolled in the study across all sites, into three different study populations. Population 1 will be comprised of at least 500 subjects from a population at risk of infection with HIV. Population 2 will be comprised of at least 500 subjects that are known HIV positive individuals. Population 3 will be comprised of at least 500 subjects from a population at low risk of HIV infection. Reveal G4 will be used to test fingerstick whole blood and venous whole blood samples from all study subjects. For enrolled subjects in Populations 1 and 3, who are of unknown HIV antibody status, a plasma sample prepared from the venous whole blood sample will also be tested with an algorithm of FDA-approved assays for the detection of HIV-1 antibodies. For Population 2 subjects who are known HIV-positive individuals, results of previous HIV tests will be obtained from the subjects' medical records. The sensitivity and specificity of Reveal G4 will be determined in fingerstick and venous whole blood relative to HIV-1 antibody status as determined by an algorithm of FDA-approved assays.

The primary analysis will involve comparison of Reveal G4 results for anti-HIV-1 in each sample matrix (fingerstick whole blood and venous whole blood) with the subject's HIV-1 antibody status as determined by FDA-approved assays. Based on the above, the sensitivity and specificity of Reveal G4 will be determined with corresponding two-sided 95% confidence intervals for both fingerstick and venous whole blood.

Conditions

HIV Infections

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Diagnostic: Reveal G4

Subjects tested with investigational devices and approved comparator assay algorithms for HIV

Group Type: EXPERIMENTAL

Reveal G4

Intervention Type: DEVICE

All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.

Interventions

Reveal G4

All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.

Intervention Type: DEVICE

Other Intervention Names

Reveal Rapid HIV-1 Antibody Test

Eligibility Criteria

Inclusion Criteria

• All subjects must be at least 18 years of age, able to sign consent form, complete the risk assessment questionnaire, and provide the required blood samples: fingerstick sample (1 drop), venous whole blood sample (1 K2 EDTA tube).

• Population 1 - Individuals at risk of HIV infection (n ≥ 500) Subjects must meet have at least one risk factor for infection with HIV
• Population 2 - Known HIV-1 positive individuals (n ≥ 500) Subjects must be a known HIV-positive individual (previous positive HIV test result)
• Population 3 - Individuals at low risk of HIV infection (n ≥ 500) Subjects must not have any risk factors for infection with HIV

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

MedMira Laboratories Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Fabienne Laraque, MD

Role: PRINCIPAL_INVESTIGATOR

New York City Department of Health and Mental Hygiene

Peter Kerndt, MD

Role: PRINCIPAL_INVESTIGATOR

University of Southern California - Los Angeles

Cheryl Berne, MD

Role: PRINCIPAL_INVESTIGATOR

Biological Specialties Corporation

Anthony LaMarca, MD

Role: PRINCIPAL_INVESTIGATOR

Therafirst Medical Center

Locations

Preventive Medicine, University of Southern California (Los Angeles)

Los Angeles, California, United States

Therafirst Medical Center

Fort Lauderdale, Florida, United States

New York City Department of Health and Mental Hygiene

Queens, New York, United States

Biological Specialty Corporation

Reading, Pennsylvania, United States

Countries

United States

Other Identifiers

MCP005

Identifier Type: -

Identifier Source: org_study_id